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1. Introduction
Throughout the years an increasing demand for smaller, lighter, 
faster, more adaptable, and durable technologies has led to the 
widespread adoption of engineered nanomaterials (ENMs) 
in a variety of industries such as food, cosmetics, textiles, 
Whilst the liver possesses the ability to repair and restore sections of dam-
aged tissue following acute injury, prolonged exposure to engineered nano-
materials (ENM) may induce repetitive injury leading to chronic liver disease. 
Screening ENM cytotoxicity using 3D liver models has recently been per-
formed, but a significant challenge has been the application of such in vitro 
models for evaluating ENM associated genotoxicity; a vital component of 
regulatory human health risk assessment. This review considers the benefits, 
limitations, and adaptations of specific in vitro approaches to assess DNA 
damage in the liver, whilst identifying critical advancements required to sup-
port a multitude of biochemical endpoints, focusing on nano(geno)toxicology 
(e.g., secondary genotoxicity, DNA damage, and repair following prolonged or 
repeated exposures).
manufacturing, electronics, energy, and 
the biomedical field. Nanotechnology 
had an estimated global market worth 
$48.9 billion in 2017 and is projected to 
reach $75.8 billion by the end of 2020; 
with the latter three industries (elec-
tronics, energy, and biomedicine) sharing 
over 70% of the global nanotechnology 
market.[1] Nanomaterials are defined as a 
natural, incidental, or manufactured mate-
rials containing particles in an unbound, 
monodispersed state, or as an aggregate/
agglomerate where 50% or more of the 
particles possess one or more external 
dimensions in the size range 1–100 nm.[2] 
Nanotechnology is based on utilizing 
materials with pre-existing beneficial prop-
erties in bulk (>500  nm) and enhancing their physico–chem-
ical properties via an increase in surface area to volume ratio 
by manufacturing these materials into particles of 1–100  nm 
in size.[3–5] However, the novel size specific physico–chemical 
properties (e.g., shape, size, crystal structure, composition, and 
surface charge) that enable ENMs to be associated with their 
advantageous applications are concomitantly causing height-
ened concerns regarding their potential adverse and unpre-
dictable effects upon the environment and human health.[3,6] 
With the continued manufacturing, integration, and extensive 
application of ENMs, the risk of release into the environment 
and human exposure increases. Human ENM exposure occurs 
through four primary routes; dermal, inhalation, ingestion, or 
injection. Once ENMs have entered the body, they can undergo 
systemic translocation if they are able to traverse the biological 
barriers and enter circulation. This often results in multiple 
sites of deposition affecting various, secondary organ systems 
such as the liver, kidneys, and spleen.[7–12]
After inhalation, ingestion, and systemic administration 
through injection, it has been shown that ENMs deposit and 
can accumulate in the liver.[13–18] Hepatic toxicology is key when 
considering both chemical and ENM exposure, as the liver is 
vital for maintaining metabolic homeostasis and detoxification 
of both endogenous and exogenous substances.[19] For example, 
the liver possesses a higher mononucleated phagocytic system 
than that found in most other tissues or even the blood. This 
was illustrated when almost all of the administered dose of radi-
olabeled [48V] titanium dioxide (TiO2)  ENMs injected intrave-
nously to healthy, female Wistar–Kyoto rats was directed straight 
to the liver for clearance.[20] However, the alveolar–blood-barrier 
and gut barrier act to reduce the rate of translocation into 
© 2021 The Authors. Small published by Wiley-VCH GmbH. This is an 
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systemic circulation, with only 4.3% and 0.6% of the adminis-
tered ENM dose entering the blood stream after 1 h. Although, 
the aim is to reduce the ENM load on surrounding tissues, 
this incidentally causes greater retention of the ENMs over 
extended periods of time.[20] It is becoming more apparent that 
translocation to secondary organs following inhalation or inges-
tion is low with <1% of the insoluble ENMs reaching secondary 
organs. The liver has been identified as a secondary organ that 
is highly susceptible to accumulation of ENMs and may result 
in liver damage and disease upon prolonged exposure.[20–22] 
Recently, Modrzynska et al. illustrated this by exposing 324 young 
adult female mice (C57BL/6) to 3.24 mg mL−1 of 10 nm TiO2, 
13 nm cerium dioxide (CeO2), and 14 nm carbon black via three 
different exposure regimes; intratracheal instillation, intrave-
nous injection, and oral gavage.[23] All three ENMs were found 
to translocate to the liver, primarily detected in the hepatic cap-
illaries (e.g., sinusoids) and appeared to have been phagocytized 
by the liver resident macrophages, known as Kupffer cells. Even 
180 days after exposure these ENMs remained within the liver 
tissue. The frequency and size of the ENM aggregates found 
in the liver tissue varied depending on the exposure method, 
suggesting not all the material is cleared easily from the liver.[23] 
Miller et  al. also demonstrated this element of bio-persistence 
in 14 healthy, human males, whereby 3.8 nm gold (Au) ENMs 
inhaled over a 2 h period remained within the blood stream 
3 months later, even after being detected in the blood of some 
volunteers as early as 15  min after exposure.[24] These find-
ings suggested that ENM translocation into systemic circula-
tion occurs rapidly and with no evidence of a time-dependent 
increase in Au ENMs present in the blood, indicating that the 
rate of translocation may be balanced by the rate of clearance.[24] 
However, slow incremental accumulation and bio-persistence 
in systemic tissues poses a potential threat to human health 
and the environment in the long-term. Evidence for this was 
demonstrated by the significant increase in DNA strand breaks 
and hepatic genotoxicity detected, only at later time points (28 
and 180 days), following inhalation exposure to carbon black.[23]
Experimental toxicology has focused on supporting “The 
3  Rs” directive to reduce, replace, and refine in vivo animal-
based experiments with the aim to develop and utilize advanced 
in vitro-based systems as more ethical, cost effective, high-
throughput alternatives for hazard characterization and risk 
assessment of chemicals and drugs. Regulations introduced by 
the EU Registration, Evaluation, Authorization and Restriction 
of Chemicals stress the need for standardized,[25] next genera-
tion in vitro tests systems that can be trusted to provide predic-
tive and reliable results. Since multiple studies have shown that 
ENMs are able to accumulate in the liver and can lead to hepa-
totoxicity upon long-term exposure, there is a need to enhance 
the longevity and realism of current in vitro liver models to 
accurately assess the hepatotoxic potential of nanomaterials. 
Ideally, these in vitro models need to emulate the physiolog-
ical environment of the human liver, as well as remain func-
tionally stable over longer periods of time to be able to sup-
port more realistic exposure scenarios (e.g., long-term single 
or repeated, low-dose exposures, sequential incubations in 
physiologically relevant simulant fluids, and the addition of 
multiple cell types). In addition, to fully reflect the in vivo situ-
ation, advanced multicellular 3D in vitro models are needed to 
recapitulate the complex, intricate organ structure and active 
metabolic function. This ensures a better understanding of 
the underlying mechanisms leading to liver injury in a natural 
exposure scenario. ENM exposure in the liver has been linked 
to the induction of lysosomal disruption, as well as mitochon-
drial disruption. The latter can lead to an imbalance in oxidative 
homeostasis, an inflammatory response involving the release of 
cytokines, recruitment of immune cells, and subsequent oxida-
tive stress. All of which can result in reduced liver functionality, 
DNA damage, and cell viability.[26]
There are a wide range of 3D in vitro liver models available 
on the market to support chemical and drug toxicity screening, 
all with benefits and limitations as extensively reviewed by 
Lauschke et  al., 2019 and van Grunsven, 2017. Based on these 
reviews, a number of these model test systems are designed in 
a manner that could deem them unsuitable for ENM associated 
DNA damage assessment in vitro. For example, the addition of 
matrices or scaffolds creates a barrier that ENMs may not be 
able to traverse, thereby preventing appropriate exposure of the 
test material to the target cells. This has the potential to result 
in dosimetry inaccuracies and uncertainty concerning the actual 
ENM concentrations applied to the culture. Another limitation 
is that current in vitro 3D liver models are often formed from 
static, fully differentiated cells (i.e., non-dividing cell models) 
which limits genotoxicity assessment; for example, it deems 
them unsuitable for use with the gold-standard cytokinesis-
block micronucleus (CBMN) assay (OECD TG487), where 
actively dividing cells are a necessity. Furthermore, there is a dis-
tinct lack of 3D in vitro liver models with the capability to eval-
uate secondary genotoxicity mechanisms induced by a chronic 
inflammatory response, which is recognized as a key mecha-
nism underlying DNA damage induction associated with ENM 
exposure in vivo.[27–29] The standard in vitro 2D and 3D mono-
culture test systems for genotoxicity evaluation are only capable 
of detecting primary genotoxicity, thereby overlooking a key 
DNA damage mechanism associated with ENM exposure that 
occurs in vivo. Therefore, in this review we focus our discussion 
on the evaluation of currently available in vitro liver models and 
their suitability for ENM-induced DNA damage screening.
2. Liver Anatomy, Physiology, and Adverse 
Outcome Pathways Associated with Hepatic 
Engineered Nanomaterial Exposure
The liver consists mostly of hepatocytes (60%), and other non-
parenchymal cell types, that influence the response toward 
ENM accumulation in the liver. Non-parenchymal cells include 
Kupffer cells (phagocytes), stellate cells (lipocytes), and liver 
sinusoidal endothelial cells (LSECs) which form the walls of 
the sinusoids (50–180 nm wide blood vessels) that carry blood 
throughout the liver.[30,31] These cells are organized into a hex-
agonal shaped liver lobule with the central vein in the middle, 
and the sinusoids radiating out to the vertices where the portal 
triad (including the portal vein, hepatic artery, and bile duct) is 
located, as indicated in Figure  1. Liver lobules are structured 
with a vast sinusoidal network to allow for the free transfer of 
oxygen, nutrients, and waste products between the hepatocytes 
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and blood traversing along the sinusoid. This results in location 
dependent partitioning of cellular functionalization, known as 
“metabolic zonation”.[31] As a result, the diverse cell populations 
and specific anatomical organization are crucial to maintaining 
a viable organ system and hepatic functionality.
The liver possesses the ability to repair and restore sec-
tions of damaged tissue following acute injury. However, pro-
longed exposure to ENMs may induce repetitive injury leading 
to chronic liver disease, whereby the regenerative capabilities 
are impaired, and the hepatocytes begin to undergo cell death 
as a result of inflammation.[19,32] There are four main adverse 
outcomes associated with hepatic injury (Figure  2), with 
liver inflammation, fibrosis, and cancer identified as adverse 
outcomes relevant to chemical and ENM toxicological risk 
assessment, and thus are key focal points when developing 
hepatic models in vitro. In 2012, the Organisation for Economic 
Co-operation and Development (OECD) launched a new initia-
tive to develop a framework to assess these adverse outcomes 
and the key events leading up to them. Adverse outcome path-
ways (AOPs) are substance-agnostic and strictly describe the 
sequence of biological events connecting an exposure to an 
adverse outcome. In other words, AOPs do not describe the 
mode of action of a specific substance, even if a substance is 
linked to AOPs by their ability to provoke the molecular initi-
ating events. A specific substance may also be used to provide 
empirical evidence for the existence of an AOP; for example, 
two AOPs describing liver pathologies have been linked to ENM 
as stressors.[33] AOPs have the potential to support systematic 
Figure 1. Diagrammatic representation of human liver physiology broken down from A) the liver itself to B) the hepatic lobules consisting of C) multiple 
liver sinusoids arranged in a hexagonal format. Created with BioRender.com.
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review and integration of highly diverse data types, including 
information from novel in silico and in vitro assays, which 
are generally not employed by risk assessors.[34] There are cur-
rently 20 AOPs describing diverse liver pathologies in the AOP-
Wiki, 17 of which are focused on liver pathologies in humans, 
including hepatotoxicity (two AOPs), liver injury (two AOPs), 
non-alcoholic steatohepatitis (one AOP), steatosis (five AOPs), 
cholestasis (one AOP), fibrosis (two AOPs), and cancer (four 
AOPs). One of the AOPs (AOP: 38 for liver fibrosis) has been 
endorsed by the OECD (indicating high quality) and is one of 
the most well-developed AOPs to date.[33] In addition, three 
AOPs for liver cancer are under review by the OECD (AOP: 
41, 46, and 220) and four are in development under the OECD 
work plan (AOP: 27 [cholestasis], 37 [cancer], 130 [hepatotoxi-
city], and 144 [fibrosis]). AOPs provide a useful tool for pre-
dicting specific mechanisms behind hepatotoxicity and should 
be considered as flexible constructs open to continual develop-
ment and refinement as more relevant data is released.[35]
2.1. Liver Fibrosis
Prolonged incidence of hepatic apoptosis and/or necrosis often 
leads to the formation of hard scar tissue in place of healthy soft 
liver tissue; a process more commonly known as liver fibrosis. 
Liver fibrosis is mediated by a plethora of growth factors and 
cytokines released by damaged or dying hepatocytes. This 
leads to the activation of integrated signaling cascades, which 
are responsible for the phenotypic transformation of quiescent 
vitamin-A storing hepatic stellate cells into contractile, prolif-
erative, and fibrogenic myofibroblast-like cells.[32,36] Thus, the 
majority of in vitro liver fibrosis models are found to comprise 
of hepatic epithelial cells cocultured independently with hepatic 
stellate cells or with the addition of other non-parenchymal cell 
types (e.g., human Kupffer cells and LSECs). Multiple models 
have been developed in an attempt to recreate a pro-fibrotic 
environment using the introduction of hepatic stellate cells, 
which have been acknowledged as the leading scar forming cell 
type in most liver injuries.[32,37] It has been frequently found 
that the greater presence of hepatic stellate cells is commonly 
linked to the proliferation of hepatoma cells and enhanced 
tumor metastasis.[38,39]
2.2. Liver Inflammation
In the liver, host defense and innate immune response is medi-
ated by the resident macrophages, Kupffer cells.[40,41] Kupffer 
cells are localized within the hepatic sinusoid and account 
for 15% of the total hepatic cell population, resulting in a 1 to 
4 ratio of Kupffer cells to hepatocytes. They are active members 
of the mononuclear phagocytic system, that serve a vital role 
in the mediation of inflammatory response, immune-mediated 
hepatotoxicity, liver injury, regeneration, and prevention of liver 
disease.[42] Kupffer cells function primarily in the ingestion and 
degradation of both endogenous and exogenous xenobiotics as 
well as senescent cells, cell debris, and other particulate matter 
present in the portal blood.[42] Furthermore, they are known to 
phagocytose pathogens, recruit neutrophils, and release both 
(pro-)inflammatory (e.g., IL-1β, IL-6, and TNF-α) cytokines 
and (pro-)fibrotic markers (e.g., TGF-β).[42,43] Kupffer cells are 
replete with toll-like receptors (i.e., TLR4, TLR2, TLR3, and 
TLR9) and have been shown to release inflammatory cytokines, 
such as TNF-α, IL-1β, IL-6, IL-12, IL-18, and IL-10 on activa-
tion with lipopolysaccharide.[41,44,45] The release of these factors 
influence and regulate the phenotypes of neighboring hepato-
cytes and other non-parenchymal cells (e.g., stellate cells and 
endothelial cells), by triggering signaling pathways that regulate 
Figure 2. An overview of the four main AOPs associated with hepatic injury. Created with BioRender.com.
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cell proliferation, viability, and cell death as well as functional 
cell changes (e.g., hepatocyte drug-metabolizing enzyme activi-
ties).[42,46,47] The presence of Kupffer cells is known to be a 
key determinant of liver fibrosis, as there is a finely balanced 
autoregulation between the release of (pro-)inflammatory and 
inflammatory mediators which in certain cases can exacerbate 
the initial damage.[45] Subsequently, Kupffer cells can facilitate 
chronic inflammation and liver fibrosis as a result of oxidative 
stress induced by cytokine release; a known adverse outcome of 
ENM exposure.
ENMs can act as exogenous reactive oxygen species (ROS)/
reactive nitrogen species (RNS) inducers that can influ-
ence intracellular calcium concentrations, activate (pro-)
inflammatory transcription factors (e.g., nuclear factor kappa 
β [NF-kβ]) and modulate cytokine production via the produc-
tion of free radicals contributing to an imbalance in the redox 
homeostasis of the cell.[48,49] It has been hypothesized that the 
increased surface area and presence of pro-oxidant functional 
groups on the ENM surface are responsible for their enhanced 
ability to produce ROS.[49,50] ENM-related oxidative stress has 
been reported to incite a series of pathological events from 
inflammation and fibrosis to genotoxicity (i.e., chromosomal 
aberrations including single and double strand breakages and 
loss/gain of whole chromosomes, point mutations, and epige-
netic changes) and carcinogenesis.[5,48,51] It is widely accepted 
that ENMs can both directly and indirectly affect intracellular 
ROS and/or antioxidant (e.g., glutathione and N-acetyl-cysteine) 
levels which are often linked with a (pro-)inflammatory 
response.[52–54]
Consequently, not only do these resident macrophages play 
an important anti-inflammatory role, but their presence within 
an advanced in vitro model allows for secondary genotoxicity 
to be assessed. Therefore, models which include multiple cell 
types, specifically Kupffer cells, in a 3D environment would be 
more beneficial to accurately assess the comprehensive effect 
of ENM exposure, accumulation within liver, and the pro-
gression toward hepatic adverse outcomes. In addition, it has 
been shown that hepatic metabolism, such as glutamine and 
albumin synthesis, cytochrome p450 enzyme activation, xenobi-
otic metabolism, and urea synthesis are often enhanced when 
cultured with macrophages.[55] Kostadinova et  al. further illus-
trated this when culturing hepatocytes with non-parenchymal 
cells (i.e., Kupffer cells, endothelial cells, and stellates cells) 
which not only displayed increased albumin synthesis, but also 
increased transferrin, fibrinogen, and urea production. Further-
more, the macrophage coculture alone had increased CYP450 
inducibility, and was more responsive to inflammatory stimuli 
and hepatotoxins when compared to the monoculture model.[56] 
This not only indicates that the inclusion of non-parenchymal 
cells may more realistically recapitulate liver structure, func-
tion, and response to toxins, but may also provide the necessary 
improvement in the predictive value of in vitro liver models.
2.3. Liver Cancer
Commonly, the etiology of multiple liver pathologies stems 
from liver fibrosis impeding liver functionality via the distor-
tion of hepatic architecture and blood flow.[32] Later stages of 
liver fibrosis are often associated with the development of 
cirrhosis and hepatocellular carcinoma; the second leading 
cause of cancer-related deaths globally, with a 55% increase 
in liver cancer mortality rates in the UK alone over the last 
decade.[32,57–59] Liver cancers are categorized as a heterogeneous 
group of malignant tumors with different histological features. 
Tumor progression can be subdivided into different “modes of 
action” (MOA) with chemicals being defined as having a non-
mutagenic or mutagenic MOA. Aflatoxin B1 for example, is a 
highly potent hepatic carcinogen, found as a contaminant of 
food, and is known to adopt a mutagenic MOA (AOP 46, AOP-
Wiki). Metabolism of aflatoxin B1 results in the formation of the 
metabolite aflatoxin B1-8,9-epoxide, that can induce pro-muta-
genic adducts believed to cause a mutation in the p53 tumor 
suppressor gene; a gene responsible for cell cycle regulation, 
initiation of DNA repair and apoptosis.[60,61] Alterations in the 
p53 gene, as well as B-catenin gene are also commonly reported 
in hepatocellular carcinoma.[62] Although each MOA may 
be toxin specific, there are common key events highlighted, 
for instance the disruption of hepatic homeostasis favoring 
reduced apoptotic activity paired with enhanced cell prolifera-
tion resulting in preneoplasmic foci and hyperplasia. These 
key events can be further advanced by a few factors including 
chronic inflammation, oxidative stress, NF-kβ activation, and 
inhibition of gap junction intercellular communication.[35]
Hepatocellular carcinoma is the most common form of pri-
mary liver cancer and originates in mature hepatocytes. Under 
normal “healthy” conditions, differentiated hepatocytes are 
quiescent and only proliferate upon hepatic injury; so much 
so they can replicate more than 50 times. It is paramount 
that current in vitro hepatic models are able to sustain long-
term culture to be able to fully assess the initial toxicological 
insult, as well as the regenerative ability of the hepatocytes to 
modulate and ameliorate the adverse reactions associated with 
injury over time. This is particularly pertinent when evaluating 
the impact of a chemical or ENM exposure on genomic integ-
rity and stability, as DNA damage can be repaired during cell 
division. Therefore, what may appear to induce genotoxicity 
following acute (24 h) exposure may no longer have the same 
effect following prolonged exposure. Prolonged exposure to a 
chemical or ENM could even result in bioaccumulation leading 
to metabolic saturation and a “tipping point” of toxicity.[63,64] 
As a result, ENMs or chemicals originally categorized as non-
genotoxic following acute exposure, may actually have unfore-
seen, long-term adverse outcomes.
3. Human Derived Hepatocytes for In Vitro 
Liver Models
With the liver being an essential organ undertaking a vital role 
in metabolic homeostasis and the detoxification of a plethora 
of endogenous and exogenous substances. It is imperative 
that robust and physiologically relevant in vitro model systems 
are established to support hepatic toxicological hazard assess-
ment following both acute and long-term exposure regimes.[19] 
A number of in vitro liver models have been developed and 
utilized to mimic the in vivo microenvironment including; 
human liver microsomes, human cell lines, primary human 
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hepatocytes (PHHs), human liver slices, and isolated perfused 
livers.[65,66] Regarded as a “gold standard” technique, often 2D 
PHHs are used to study hepatotoxicity of chemicals in vitro. 
However, the hepatic phenotype rapidly declines over time 
showing fast dedifferentiation and so they are deemed unfit 
for long-term exposure studies in a 2D setup. Even with addi-
tional features (e.g., an extracellular matrix [ECM] protein sand-
wich culture) to enhance the physiological relevance of the 2D 
in vitro microenvironment, PHH cultures lose their hepatic 
functionality after 14 days in culture, with evidence of reduced 
albumin and urea production.[67] Similarly, 2D systems devel-
oped with human hepatic cancer cell lines like HepaRG or 
HepG2, were found to exhibit reduced hepatic characteristics 
and metabolic activity, specifically cytochrome P450 (CYP450) 
enzymes (e.g., CYP1A2 and CYP3A4).[68–70] Reduced expres-
sion of phase I enzymes, such as CYP1A2 and CYP2E1, and the 
subsequent decline in metabolic activity has resulted in some 
pro-mutagenic compounds (e.g., styrene, aromatic amines, and 
2,4-diaminotoulene) being difficult to detect with 2D systems 
alone.[71–73] Overall, 2D liver models allow for rapid low-cost, 
high-throughput screening of chemicals or ENMs and are suit-
able for the evaluation of acute toxicity. However, 2D systems 
generally show decreased hepatic phenotype, a reduced meta-
bolic capability, both of which diminish further over extended 
culture periods, and do not emulate the complex intricacies of 
the 3D organ system (e.g., intracellular interactions and bile 
canaliculi). These factors alone have the potential to limit their 
predictivity for identifying hepatotoxicants. With the longevity 
of 2D hepatocyte models restricted to less than two weeks, they 
do not allow for long-term, repeated exposure scenarios to be 
conducted thereby missing the evolution of toxicity during 
chronic conditions. To study the hepatotoxic effects of ENM 
exposure in vitro, a robust 3D model that has demonstrated 
long-term stability, liver functionality, and allows for both acute, 
chronic, and repeated exposure regimes is required.
It is widely accepted that 3D in vitro liver models better 
mimic the in vivo complexities and intricate multicellular inter-
actions than their 2D counterparts.[19,67,74,75] These features 
improve the longevity of in vitro hepatic models allowing for 
long-term and repeated exposure regimes to be investigated. In 
addition, these features have enabled enhanced physiological, 
organo-typic features like bile canaliculi, active transporter pro-
cesses, and CYP450 drug-metabolizing capabilities to develop. 
As a result, the physiological relevance and thereby the pre-
dictivity of the models has improved. In a 3D setup, PHHs 
remain the “gold standard” for hepatic hazard assessment and 
are considered the most sensitive cell type compared to other 
in vitro liver cell models; HepG2, HepaRG, and Upcyte hepato-
cytes.[65,76,77] PHHs are considered to possess the closest rep-
resentation of active hepatic metabolism (e.g., expression of 
phase I and phase II enzymes, transporters, and nuclear fac-
tors) similar to that found in vivo, with CYP450 activity much 
greater than that observed in hepatic cell lines. However, PHH 
models exhibit interindividual donor variation and are known 
to undergo significant de-differentiation during long-term cul-
ture.[77] Interlaboratory comparisons were conducted using 
HepG2, HepaRG, Upcyte, and PHH models to determine if 
the different in vitro hepatic models could correctly identify the 
nine drug-induced liver injury (DILI)-implicated compounds 
from the four non-DILI-implicated compounds. Sison-Young 
et  al., found that PHHs positively identified eight out of the 
nine DILI compounds, yet this was closely followed by HepG2 
cells which correctly identified six out of the nine (>66%) chem-
ical compounds.[77] Due to the expensive, complex, and variable 
nature of the PHH models, demand for research and further 
development of hepatocyte-derived cell line models has been 
established.
Immortalized human cell lines are sourced from one donor 
and are often genetically modified or transformed in a manner 
that ensures they maintain an element of their original phe-
notype.[68] These cultures tend to be readily proliferating, ame-
nable to subculture, resistant to de-differentiation, and are 
far less sensitive to environmental changes than the PHHs. 
These characteristics, in line with being relatively inexpensive 
and easily accessible, highlight cell line-derived 3D models as 
valuable tools for early-stage drug, chemical, and ENM tox-
icity screening in vitro. A number of human immortalized cell 
lines, like HepG2, HepaRG, and Huh7, have been successfully 
utilized across a variety of 3D platforms and have displayed 
more liver-like functionality and phenotypic consistency than 
their previous 2D counterparts.
More recently, both HepaRG and HepG2 cell lines appear 
to be the most frequently studied cell lines and have been 
readily used in a range of systems, from spheroids in the 
hanging drop format and ultralow adhesion plates through to 
scaffold-based (e.g., hydrogels, Matrigel) or bioreactor systems 
that offer more structural support to the 3D culture.[68,69,78–81] 
HepaRG cells originate from hepatic-differentiated, grade-one 
Edmonson hepatocholangiocarcinoma and have been shown 
to retain their bipotent hepatic progenitor-like characteristics, 
with a high level of differentiation and expression of typical 
hepatic functions, including CYP-dependent metabolism, CYP 
induction, and drug transporter expression.[68,82] Furthermore, 
HepaRG possess expression of a major organic anion trans-
porter (MRP-2) involved in bile excretion, together with the 
ability to form tight junctions, both of which provide the basis 
for the formation of functional canicular structures allowing 
for the passage of bile.[68] It has been suggested that these 
HepaRG 3D systems exhibit enhanced metabolic functions as 
a result of both selective hepatocyte differentiation and accel-
erated maturation induced by limited cellular proliferation. 
Evaluation of these HepaRG cells for drug and chemical tox-
icity testing showed a similar response to PHH cultures when 
assessing the effect of acetaminophen; with a high activation 
of genes related to liver damage as compared to HepG2 cells, 
indicating this cell line could serve as a surrogate for PHHs. 
Gunness et al., demonstrated this further when HepaRG sphe-
roids exposed to 0.5–80  mmol  L−1 of acetaminophen for 24  h 
exhibited a similar dose-dependent response with an EC50 value 
of 2.7  mm which reflects the concentration observed in vivo. 
This is suggested to be directly correlated to the high levels of 
CYP2E1 activity producing N-acetyl-p-benzoquinone imine in 
abundance.[78] Although several HepaRG-based 3D models have 
been reported to better mimic in vivo-like microenvironments 
they do not parallel the metabolic competence and biological 
relevance of that found in the PHH models, lacking a stable 
genetic background and the ability to proliferate. Conway et al., 
demonstrated this with an average binucleate frequency of less 
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than 10.0% regardless of the concentration and exposure time 
to the actin polymerization inhibitor, cytochalasin B. This was 
deemed unsuitable in accordance with OECD Test Guideline 
487 for the CBMN regulatory standard genotoxicity assessment 
in vitro.[83,84]
HepG2 cells, when cultured in an advanced setup may also 
represent a suitable alternative to PHHs for in vitro high-
throughput toxicological screening. HepG2 cells have been 
shown to parallel if not outperform HepaRG cells in the detec-
tion of hepatotoxicants. Research has shown that HepG2 cells 
have a sensitivity of 80% to hepatotoxins and can correctly 
identify 66.7% of DILI-implicated compounds.[77,85] HepG2 cells 
are non-tumorigenic, epithelial-like hepatocytes derived from 
a hepatocellular carcinoma and can biotransform numerous 
xenobiotic compounds. This cell line has been well character-
ized and, contrary to previous literature, found to share similar 
gene expression profiles as PHH cultures for drug-metabolizing 
enzymes and transporters (DMETs) when cultured in a 3D 
format.[77,86] HepG2 cells are easily accessible, cost-effective, 
and offer limited intercellular variation whilst retaining a high 
level of proliferation and phenotypic stability. They are able to 
secrete typical liver plasma proteins including albumin, fibrin-
ogen, and transferrin, but often lack sufficient gene expression 
of some essential phase I and II biotransformation enzymes, 
critical for certain CYP450 enzymes. Guo et  al., demonstrated 
this when they assessed the expression of 251 DMETs including 
84 phase I genes, 83 phase II genes, and 84 phase III genes 
in four cell lines (HepG2, Hep3B, SK-Hep1, and Huh7). In 
PHH, 69 out of the 84 phase I genes were detected in RNA 
preparations whilst only 44 phase I genes were expressed 
highly enough by HepG2 cells resulting in a reduced capability 
to catalyze oxidation, reduction, hydrolysis, cyclization, and 
decyclization reactions.[65] However, the transition from cul-
turing HepG2 cells in a 2D format compared to a 3D format 
has enhanced their hepatic phenotype significantly. Shah et al. 
illustrated this enhanced metabolic capacity of HepG2 cells, 
when cultured in a 3D environment, with a 6-fold increase in 
CYP1A1 activity and a 30-fold increase in CYP1A2 compared 
to the equivalent 2D format.[70] Furthermore, the enhanced 
activity of the phase I enzymes resulted in greater sensitivity to 
metabolically activated genotoxicants. Whereby, no genotoxicity 
was observed in 2D following 24 h exposure to 5 µm of amino-
1-methyl-6-phenylimidazo(4,5-b)pyridine, yet in 3D a significant 
increase in fixed DNA damage was observed.[70] This highlights 
that it is critically important to not solely consider the building 
blocks of the model (i.e., the cell line and culture supplements) 
but also the architecture of the system (i.e., 3D cellular arrange-
ment) and how this may enhance the primary features of the 
original foundations (e.g., cellular polarization, intercellular 
interactions, and canicular structures).
4. Three-Dimensional In Vitro Liver Model 
Systems
The variety of liver cell lines described in Section  3 can be 
adapted to suit multiple 3D platforms. Some examples of 
such advanced culture systems include the formation of stem-
cell derived hepatic organoids, hepatic spheroids, bioreactor 
systems, microchips (e.g., organ-on-a-chip), bioprinted 
organ systems, and microfluidic flow models. All of which 
improve the longevity and differentiation of the cell lines into 
enhanced, fully functional hepatocytes within a more physi-
ologically relevant setup. However, the majority of these novel 
approaches lack a robust, economical, and simple design. 
They often involve laborious assembly, limited accessibility to 
specific resources necessary for model construction, demon-
strate increased variation, and require expensive equipment 
and skilled expertise. These challenges represent barriers for 
the use of such 3D model systems in high-throughput and/
or screening approaches to facilitate predictive toxicology, and 
many of these models are not able to support genotoxicity 
assessment.[69]
One method that appears to overcome many of the chal-
lenges faced in 3D model design for hepatocyte systems is the 
development of liver spheroids, also known as microtissues. 
Hepatic 3D spheroid models are generated when monodis-
persed cells self-assemble into compact spherical structures. 
They are used frequently in vitro hepatic toxicology as the tech-
nique is simple by design, highly adaptable, and is shown to 
recapitulate the liver microenvironment well.[76,87] One simple 
technique to develop 3D liver spheroids is through the use of 
gravity in the hanging drop method as illustrated in Figure 3, 
or the use of ultralow attachment plates which are a less labo-
rious, but more expensive alternative. Spheroids produced via 
these techniques often form extensive intracellular interac-
tions and produce their own ECM. Another approach to gen-
erate 3D structures in culture is by plating cells within an ECM 
using a scaffold, such as Matrigel.[88] With this scaffold-based 
method, multiple spheroids can be generated within one well, 
but they often vary more in size, shape, and number compared 
to the scaffold-free methods. However, a low-acyl gellan gum 
functional polymer matrix has been found to produce uniform 
spheres of 115.5 ± 1.7 µm in diameter, which can also be used 
with human induced pluripotent stem cells.[89] In addition, for 
some cell types including HepG2 cells, a scaffold can help to 
improve the hepatic phenotype and arrest proliferation, thereby 
enabling long-term stability.[90] Nonetheless, using a scaffold 
can add additional complexity to harvesting the cells for bio-
chemical endpoint analysis as well as hinder the uptake and 
penetrance of ENMs in particular when compared to scaffold-
free methods.
The versatility of these basic 3D model systems offers the 
potential for further advancements to emulate true in vivo 
conditions. Examples of this have been seen in the introduc-
tion of fluidic-based systems to recapitulate blood flow,[91,92] or 
the addition of non-parenchymal cell types to mimic the com-
plex interplay of immunity, cell signaling pathways, and feed-
back loops.[32,93] Yet, it is worth noting that the greater human 
resemblance and complexity the in vitro models possess, often 
makes it more difficult to culture, manipulate, and apply in a 
hazard characterization setting. Furthermore, these modifi-
cations do not fully resolve a major limitation of the current 
in vitro 3D systems; the lack of complex vascular structures 
crucial to efficient oxygenation, transport of nutrients, and 
waste removal from hepatic tissues, which occur in vivo. In an 
attempt to counteract this, cells grown in 3D culture perform 
these functions by diffusion or zonation alone. As a result, the 
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longevity of these in vitro 3D model systems is often limited 
by cell viability as the restricted oxygen and nutrient diffusion 
in conjunction with an accumulation of waste at the core 
of the microtissue, as shown in Figure  4, causes a necrotic 
core to develop. The limit of this diffusion is thought to be 
≈100–150 µm of tissue.[94,95] Based on this, a number of in vitro 
3D models have been developed to be much smaller in order 
to limit cellular proliferation, the progression of necrosis, and 
extend the longevity of the cultures. Extending the longevity of 
the 3D model systems is an important factor when considering 
these in vitro liver models for use in ENM toxicity testing and 
hazard assessment. The continuous inclusion of ENMs into 
everyday applications assures that humans will be exposed to 
low doses of these materials on a regular, repeated basis over 
long durations of time. Therefore, there is a greater need for in 
vitro models to remain viable over extended periods of culture. 
A feature that a number of 3D liver models do not have without 
reducing the proliferative capacity of the model or increasing 
the complexity and subsequent production costs of that model.
5. In Vitro Liver Model Systems for Engineered 
Nanomaterial Hazard Assessment
Some of the 3D liver in vitro systems described in Section  4 
have already been applied for the evaluation of ENM-induced 
hepatotoxicity as shown in Table  1. However, many of the 
advanced 3D test systems have been designed on the basis of 
testing chemicals alone and do not take into consideration the 
challenges associated with testing ENMs. For example, a par-
ticular challenge is the variable sedimentation and diffusion 
rates associated with different ENMs (e.g., size, shape, and 
density) and variability based on the individual test system 
(e.g., exposure medium, scaffold material, and construction 
variabilities in establishing 3D models). This often results in 
an unequal distribution of ENMs across the test system or on 
Figure 3. Illustration of a 3D in vitro liver spheroid model developed by Llewellyn et al., 2020, and formed via the hanging drop technique prior to 
transfer into the well plate for ENM exposure. Microscopy images of A) HepG2 monoculture spheroid and B) HepG2/Human Kupffer cell coculture 
spheroid taken 4 days after seeding (i.e., the day of ENM or chemical exposure) using a 10× objective with a light microscope and fluorescent confocal 
microscope, respectively. Green fluorescence represents the CD68 (ab222914, Abcam, UK) positive staining for the human Kupffer cells, whilst the blue 
fluorescence signifies the DAPI nuclear staining. The scale bars represent 100 µm. Created with BioRender.com.
Figure 4. Diagrammatic representation of the nutrient gradient exhibited 
within 3D liver structure. Cellular zonation illustrated by the darkening 
shades of red toward the center of the 3D structure, indicating a reduction 
in cell viability as a result of reduced oxygen (O2), nutrients, and growth 
factors and elevated carbon dioxide (CO2) concentrations indicated by 
the graduated yellow arrows.
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Table 1. 2D, 3D, and advanced in vitro liver models utilized for ENM toxicity screening.




Cell type used Exposure time ENMs tested
Pros Cons




(Yang et al., 2019) HL-7702 Single (24 h) Silica NPs
(Lorscheidt et al., 
2019)
HepG2 Single (24 h) SiO2
(Chen et al., 2019) HepG2 Single (24 h) ZnO
(Cornu et al., 
2018)








Single (24 h) TiO2, DQ12,  
carbon
(Gao et al., 2020) hiPSC-HLCs Single (24 h) Ag
PHH sandwich + bile canaliculi network
+ high-throughput
− short-term only







+ multi cell type




+ equal spheroid size
+ multi cell type





















+ multi cell type
+ equal spheroid size













HepaRG Single (6h, 24h) Ag
Micromold + long-term
+ multiple spheroids
+ multi cell type
+ equal spheroid size










+ multi cell type
− possible hindrance 







HepG2 Single (24h, 
72h)
Ag, SiO2, ZnO











+ multi cell type
− low-throughput (Li et al., 2019) PRH Repeated  
(3 and 7 days)
SPION
(Esch et al., 2014) HepG2-C3A 
co-culture
Single (24h) Carboxylated  
polystyrene NPs
Bioprinted + 3D architecture − low-throughput
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the cell surface of the 3D liver model, which has the potential 
to cause dosimetry inaccuracies and uncertainty concerning 
the actual ENM concentrations applied to the culture. This 
limitation can be overcome theoretically using the in vitro sedi-
mentation, diffusion, and dosimetry model, or its more recent 
derivatives (e.g., ISD3) often referred to with ENM suspen-
sion exposures.[96,97] A further complication with ENM hazard 
assessment, is the changeable nature in the physico–chemical 
characteristics of the materials themselves alongside their ten-
dency to aggregate or agglomerate, as this makes predicting 
biological interactions and cellular uptake difficult. With these 
challenges in mind, it is not surprising that, unlike chemicals, 
ENMs do not translocate and permeate the inner cell layers of 
the 3D structures as efficiently. Albeit, not without its limita-
tions, technological advancements in in vitro 3D model ENM 
hazard assessment techniques provide potential alternatives to 
reduce the reliance on animal-based testing methods.
Dubiak-Szepietowska et  al. showed the applicability of 3D 
HepG2 cells for ENM toxicity studies. Here, HepG2 cells were 
plated in three different hydrogels (Matrigel, collagen type 1, 
and gelatin) resulting in the formation of 3D spheroids with 
improved hepatic phenotype and function, as demonstrated 
by an increase in albumin and urea production after 10 days 
of culture compared to the 2D system.[88] However, these sphe-
roids displayed a decreased sensitivity toward ENM exposures 
for both 24 and 72 h compared to conventional 2D culture. This 
could be explained by improved cell-to-cell interactions and 
intercellular signaling in 3D culture, which not only encour-
ages the cells to differentiate into more complex structures 
but alters the signaling (and possibly repair) activities in a cell. 
More importantly however, the hindered diffusion of ENMs in 
the hydrogels are likely to result in lower cellular ENM uptake 
during the acute phase.[88] Hence, the use of 3D models formed 
with scaffolds or matrices may not be suitable to study the 
effects of ENM exposure.
Nonetheless, 3D human liver microtissue models are shown 
to identify adverse reactions after repeated long-term exposure 
to a range of ENMs.[74,93] A study by Kermanizadeh et al. (2014) 
showed that scaffold-free primary human 3D liver microtissues, 
consisting of both PHHs and non-parenchymal cells, were able 
to identify hepatotoxic effects of ENMs during a 15-day, repeated 
exposure regime. Here, predominantly, cytotoxicity was seen 
after prolonged or repeated exposure scenarios and not with 
single exposures alone, highlighting the importance of having 
a long-term stable in vitro liver model to recognize ENM-
induced hepatotoxicity. A more recent study, by Kermanizadeh 
et al. (2019), evaluated the recovery capabilities of liver spheroid 
microtissues after 7- or 14-day repeated ENM exposure to zinc 
oxide (ZnO), TiO2, and CeO2 and the positive control quartz 
containing ≈87% crystalline silica (DQ12). During the recovery 
periods, a reduction in cytokine production was observed, sug-
gesting the microtissues could recover and emulate an element 
of liver regeneration as found in vivo. Interestingly, darkfield 
imaging highlighted that the ENMs could translocate through 
the outer surface cell layers of the spheroid and even penetrate 
the core, providing evidence to support that ENM exposure on 
3D model systems can be comprehensive.[74] However, after 
two weeks of culture a decline in the viability of the untreated 
control suggests the 3D model system was not as stable as first 
thought and should be used no longer than 14 days for long-
term ENM exposure screening.
Although this study highlights the suitability of this PHH 
3D liver model for longer-term ENM hazard assessment, 
Llewellyn et  al. also demonstrated that HepG2 cells could be 
cultured in a hanging drop format for up to 14 days without 
the need for specialized equipment or scaffolds.[80] The liver 
spheroids were ≈500 µm in diameter and able to support both 
acute (24  h) and longer-term (5 days) ENM exposure regimes 
without a significant reduction in cell viability in the untreated 
controls. Furthermore, HepG2 spheroids seeded at 4000 cells 
per spheroid, were found to retain sufficient proliferative capa-
bilities to be able to support the CBMN assay for genotoxicity 
assessment following both chemical (aflatoxin B1) and ENM 
(TiO2 and Ag) exposure;[80,83] a feature that other in vitro 3D 
hepatocyte models are currently unable to offer. Interestingly, 
another HepG2-based spheroid model was utilized to com-
pare the cytotoxicity and genotoxicity using the comet assay, 
of Ag, ZnO, and TiO2 ENMs following acute 24 h exposure.[98] 
In both 2D and 3D cultures the relative cell viability decreased 
in a concentration-dependent manner after exposure to Ag and 
ZnO ENMs, whilst TiO2 had no effect. For ZnO ENMs, the 
calculated EC50 values were in the same range for 2D and 3D 
cultures: 10.1 and 16.2  µg  cm−2, respectively. Yet, the induced 
cytotoxicity of Ag ENMs was higher in 2D cultures compared to 
3D cultures, with EC50 values of 3.8 and >30.0 µg cm−2, respec-
tively.[98] This could be attributed to the high levels of agglom-
eration observed with the increased hydrodynamic diameter of 
Ag ENMs from 37.3 ± 0.04 to 508.8 ± 29.5 nm further reducing 
the penetrative capabilities of the Ag ENMs into the compact, 
3D spheroid structure.
Despite the advantages of using 3D models, their compact 
intricate structure can result in the uneven distribution and 
hindered penetration of ENM across the 3D structures.[99–102] 
A recent study by Fledderman et  al. (2019) showed that SiO2 
nano particles could only penetrate 20  µm, corresponding 
to three cell layers, into the HepG2 spheroids created via the 
hanging drop method. In concordance, a study by Huang et al. 
demonstrated that Au nanoparticles showed size dependent 
penetration into tumor tissue or spheroids, where nanoparticles 
of 15  nm or larger were unable to penetrate the tissue.[101] As 
highlighted by these two studies and the aforementioned PHH 
study undertaken by Kermanizadeh et al. (2019), the transloca-
tion capabilities and localization of ENMs can vary considerably 
from model to model and so should be characterized for each 
model independently to ensure an accurate representation of 
ENM distribution is carried out as seen in vivo.
Whilst screening ENM cytotoxicity using in vitro models has 
been performed routinely, not many have been able to adapt 
and utilize the 3D liver models for ENM associated genotox-
icity. Most ENM associated hepatic genotoxicity studies have 
been assessed in vivo or with 2D hepatic, monoculture systems 
in vitro. When performing a literature search using the terms 
“3D in vitro liver model nanomaterial genotoxicity,” only 9 pub-
lications were identified in PubMed, whilst “3D in vitro liver 
model nanomaterial toxicity” retrieved 19 relevant publications 
and “3D in vitro liver model toxicity” returned 189 publica-
tions. This highlights the novelty of 3D in vitro liver models 
being utilized for ENM genotoxicity hazard assessment and a 
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clear knowledge gap for further research and development to 
be undertaken.
6. In Vitro Engineered Nanomaterial Associated 
Genotoxicity Assessment
Genotoxicity arises as a result of DNA damage induced by an exog-
enous agent which is subsequently fixed as permanent mutations 
to the genetic information within a cell. These mutations may 
lead to the incorrect transcription of DNA to mRNA required for 
protein translation. When a mutation alters the genetic coding 
for a protein, it can affect the assembly and subsequent func-
tion of that protein. Erroneous alterations to proteins that play a 
critical role in the body can disrupt normal development or cause 
malignancies, and other pathogenic effects via mechanisms like 
uncontrolled proliferation, mitochondrial dysfunction, or defective 
metabolism.[103] Multiple in vivo and in vitro studies have reported 
that some ENMs exhibit clear cytotoxic, (pro-)inflammatory, and 
sometimes genotoxic effects, thus raising concerns as to the long-
term implications on human health.[104,105] Exposure to ENMs can 
induce genotoxicity via primary and/or secondary mechanisms. 
Primary mechanisms dominate in vitro ENM associated geno-
toxicity testing, whilst secondary genotoxicity is recognized as the 
main genotoxic mechanism in vivo.[28,29] Primary mechanisms can 
be classified into direct or indirect genotoxicity:
• Direct mechanisms of genotoxicity involve DNA damage 
caused by the direct, physical interaction of ENMs with the 
chromosomes or DNA molecule itself.[27,28]
• Indirect mechanisms of genotoxicity arise from ENM medi-
ated induction of ROS/RNS or the release of toxic ions from 
soluble ENMs (e.g., zero-valent metals, like silver) that can 
interfere with DNA complexes or cell cycle proteins (e.g., 
spindle apparatus and centrioles) that can hinder cellular 
replication, DNA repair, and division.[27,28]
Genotoxicity is extensively linked to elevated ROS and an 
imbalance in oxidative homeostasis following ENM exposure. 
ROS can interact directly with DNA, disrupt DNA complexes, 
and cause DNA strand breaks, chromosomal aberrations, and 
alterations; all of which can induce mutations.[5,48,51,63] Sec-
ondary genotoxicity arises in vivo as a result of chronic inflam-
mation caused by the recruitment and activation of immune 
cells (e.g., macrophages and neutrophils). This cascade results 
in the continued release of inflammatory mediators and exces-
sive ROS produced during phagocytosis, both of which sub-
sequently induce DNA damage in the surrounding epithelial 
tissue.[27,106]
ENM associated genotoxicity can differ between in vitro 
and in vivo settings, as the latter is reliant on biokinetic 
patterns and often involves interaction between multiple 
cell types. However, DNA damage and associated genotox-
icity can be assessed in vitro using a range of assays that 
test particular biochemical endpoints or target specific 
DNA damage mechanisms, allowing for a more controlled 
and targeted approach. Magdolenova et  al. found that only 
2.58% of articles on “NP toxicity” describe genotoxicity 
studies; of the 112 articles found, 94 were in vitro-based 
genotoxicity studies whilst 22 were in vivo studies.[106] The 
comet assay, CBMN assay, y-H2AX, Green Fluorescent Pro-
tein (GFP)-gene reporters, and transcriptomic screening are 
a few examples of common techniques utilized to assess 
gene activation/deactivation, DNA damage, and genotoxicity 
in vitro. The in vitro mammalian cell gene mutation tests 
using the HPRT and XPRT Genes (TG476) and the in vitro 
mammalian cell micronucleus test (TG487) have undergone 
rigorous validation and have recognized OECD test guide-
lines. As described in Table  2, not all of the genotoxicity 
assays available are acceptable for regulatory purposes and 
are, therefore, only deemed suitable for research purposes 
in order to provide an insight into the underlying mecha-
nisms behind ENM associated genotoxicity. Table  1 further 
highlights the benefits and limitations to the current assays 
available to assess DNA damage and genotoxicity in vitro 
that have the potential to be adapted for use with 3D hepatic 
model systems.
7. Adapting Three-Dimensional In Vitro Liver 
Models to Support Genotoxicity Assessment
Genotoxicity can be assessed using a number of techniques, 
as highlighted in Table  2 of Section  6. Each technique has 
specific applications and genotoxicity targeted endpoints 
(e.g., chromosome aberrations or fixed DNA damage foci), 
but not many have been adapted for use with 3D in vitro 
liver models, let alone been tailored to support ENM expo-
sures, as shown by the limited publications in the scientific 
literature to date. Of the genotoxicity assessments performed, 
there are principally three techniques which have been suc-
cessfully adapted to support ENM associated genotoxicity 
in 3D liver models: the CBMN assay, the comet assay, and 
bacterial artificial chromosome (BAC)–GFP reporter cell line 
systems.
The CBMN assay is a reliable and multifaceted technique 
that measures gross chromosomal damage illustrated by the 
frequency of micronuclei present.[107] It is a “gold standard” 
technique for assessing in vitro DNA damage and genotox-
icity and is described by the OECD Test Guideline 487.[84,108] 
The CBMN assay can readily detect both aneugenic and clas-
togenic acting compounds alluding to potential DNA damage 
mechanisms. Aneugenic compounds result in the loss or addi-
tion of whole chromosomes, whilst clastogenic compounds 
induce gene mutations and structural aberrations, including 
fragmentation and rearrangement of a chromosome.[109] Fur-
thermore, the cytostatic status of the cell can be determined 
using the ratio of mononucleated, binucleated, and multinu-
cleated cells to calculate the cytokinesis-block proliferation 
index.[84,110,111] Although a popular and reliable method for 
assessing genotoxicity, the CBMN assay is rarely used with 3D 
in vitro hepatic models as many are static models based on 
primary or differentiated hepatocytes (e.g., HepaRG) which do 
not have the capability to actively proliferate. As fixed DNA 
damage is only visible after the cells have undergone one cell 
cycle (i.e., undergone division), with a low binucleate fre-
quency, the CBMN assay cannot be used to accurately predict 
genotoxicity. Conway et  al. highlighted this when assessing 
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Table 2. Current, available assays used to assess DNA damage and genotoxicity in vitro that have the potential to be adapted for use with 3D hepatic 
model systems.




Advantages Disadvantages Adapted  
to support  






Mutagenicity test system used  
for the detection of small membrane-
bound DNA fragments, known as 
micronuclei, originating from the loss 
of a whole chromosome or fragments of 
a chromosome (lacking a centromere). 
Number of micronuclei visible in the 
cytoplasm of interphase cells is scored. 
(OECD, 2016)





Assessed; Allows for 
DNA repair; Evaluation 
and Quantification of 
both structural and 
numerical chromosomal 
damage; High Sensitivity 
when coupled with 
Fluorescent In Situ 
Hybridization; Supports 





Yes OECD Approved Test 
Guideline for Assessing 
Genotoxicity In Vitro – 





In vitro test system used to identify 
substances that cause structural 
chromosome aberrations, including 
changes to chromosome  
number and/or chromosomal  
deletions, inversions and  
translocations. (OECD, 2016)
Fixed DNA Damage; 
Chromosome  
Mutations including 
Numerical and  





of Chromotid and 
Chromosome  
type Aberrations;  







No OECD Approved Test 
Guideline for Assessing 
Genotoxicity In Vitro – 
Guideline 473  
(OECD, 2016)
Point Mutation 






Gene mutation tests identify  
substances that induce point  
mutations on the X chromosome,  
which subsequently inactivates or  
modifies the function of the gene 
product via base pair substitutions or  
frameshift mutations. Evidence  
of this mutation can be seen in the 
absence of the functional gene  
product (protein) that affects the  
growth of mutant cell colonies in 
selective media. (OECD, 2015)
Fixed DNA Damage; 
Point (Gene) Mutation; 
Clastogenicity
Detects Point and 
Chromosomal  





(Duration: 6 Weeks); 
Open to Human 
Subjectivity in Scoring 
Procedure; Only 
specific (male) cell 
types are suitable for 
detection  
of gene mutations
No OECD Approved 
Test Guideline for 
Assessing Genotoxicity 




Alkaline (>pH 13)  
single-cell gel  
electrophoresis based  
assay used to  
identify substances that induce DNA 
damage, including both single and 
double stranded breaks in eukaryotic 
cells.
DNA Strand Breaks;  
Alkali Labile Sites;  
Oxidized and  
Alkylated Base  
Regions
Detects DNA damage; 
Fast; Cost Effective;  
High-throughput  
screening
Does not measure  
fixed DNA damage 
lesions as the 
damage it detects 
has the potential to 
be repaired; High 
variability  
due to lack of 
standardized protocol
Yes There is no standardized 
method for the in vitro 
comet assay, but there 
is an OECD Approved 
Test Guideline for the 
In Vivo version of the 
Alkaline Comet Assay 
only – Guideline 489 
(OECD, 2016)
Transcriptomics Techniques, using microarray,  
qRT-PCR or RNA-seq, analyze the 
quantity of messenger (m)RNA 
molecules present, which reflects the 
genes that are being actively expressed 




Entire Genome  
assessed;  
Elucidation of DNA 














These systems are based on a Green 
fluorescent protein (GFP) hybridized 
gene reporter used to identify the 
expression of specifically targeted genes 
(e.g., p53, γ-H2AX), which fluoresce 
green if the gene is actively expressed in 
individual eukaryotic cells.
Gene Transfer and 
Expression
High-throughput; Can 
be coupled with Live 
Imaging
Requires Transgenic 
Cell Lines; Often 
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the suitability of HepaRG and HepG2 cell lines to support the 
CBMN assay, whereby HepaRG, regardless of cytochalasin 
B concentration and exposure time, only yields a binucleate 
frequency of <10% whilst HepG2 exhibited a binucleate fre-
quency of >30%.[70,73,83]  As a result, DNA damage and geno-
toxicity assessment are usually performed using alternative 
methods such as the comet assay or integrated GFP-reporters. 
However, recently the CBMN assay has been successfully 
used to detect DNA damage and genotoxicity in 3D HepG2 
hanging drop spheroids following acute exposure to aflatoxin 
B1 and benzopyrene.[70] This research further highlighted the 
importance of enhanced metabolic competence in 3D model 
systems relative to 2D models when assessing toxicological 
outcomes associated with compounds which require meta-
bolic activation. Even when restricted by the necrotic core, the 
proliferative capacity of the HepG2 cells on the outer surface 
of the spheroids is still able to support the CBMN assay.[70,80] 
Furthermore, the micronucleus assay was adapted and used to 
successfully support both acute (1 day) and long-term (5 days) 
genotoxicity hazard assessment of 10 µg mL−1 of TiO2 and Ag 
ENMs.[80] Careful consideration must be taken when using 
the “cytokinesis-block” version of this assay for long-term 
or repeated exposure regimes though, as any DNA damage 
induced within the first few cell cycles is distributed across 
the mononucleated cell population, as opposed to being 
retained and scored within the binucleated cells. This could 
lead to false negatives, as the DNA damage accumulated over 
the period of chronic exposure can be masked. As a result, 
Llewellyn et  al. suggested that the mononuclear version of 
the micronucleus assay may be more suitable for long-term 
or repeated exposure regimes. The micronucleus assay is a 
valuable tool when assessing the genotoxic effects associated 
with both acute and long-term ENM exposure, as to the best 
of our knowledge, there has been no reported interaction 
between the assay and ENMs.
The comet assay is commonly used for assessing DNA strand 
breaks and oxidized or alkylated base lesions following ENM 
exposure in order to provide an indication of the mutagenic 
and carcinogenic potential of the ENM under evaluation.[76] 
The comet assay can assess a few hundred to several thousand 
strand breaks per eukaryotic cell; a biologically relevant sensi-
tivity range which can detect DNA damage extending from low, 
endogenous levels to high, almost lethal levels of damage. Pre-
vious work, using PHH models have found that exposure to 
ZnO, Ag, TiO2, and multiwalled carbon nanotubes (MWCNT) 
induced DNA damage at varying exposure concentrations 
(0.5–8.0 µg mL−1 of ZnO and Ag, and 16–250 µg mL−1 of TiO2 
and MWCNT), with ZnO and Ag exhibiting the greatest DNA 
damaging potential and subsequent repeated ENM exposure 
elevating the DNA damage levels significantly.[93] Similarly, 
Elje et  al. found that ZnO and Ag ENMs, which both dis-
play a tendency to dissociate into ions, were found to exhibit 
a concentration-dependent increase (0–75  µg  cm−2) in DNA 
strand breaks following acute, 24 h exposure in both 2D and 
3D HepG2 cultures. However, no effect of DNA damage was 
observed after exposure to TiO2 ENMs in either 2D or 3D 
HepG2 cultures.[76] Whilst these studies highlight that the PHH 
and HepG2 3D models predict a similar ENM genotoxicity out-
come, they also show that the comet assay can be applied with 
multiple 3D models contributing to its popularity as a method 
for assessing ENM associated genotoxicity in vitro. Unlike the 
CBMN assay mentioned above, the comet assay is not restricted 
by cells that do not proliferate, in fact, it is a useful tool to cir-
cumvent this limitation. The main drawback of this assay is 
that whilst it highlights the potential of an exogenous agent 
to cause DNA damage, it does not take into account the ability 
of the cell to undergo DNA damage repair. Thus, some of the 
lesions detected by the comet assay may be transient, which 
may result in misleading positive results. To date, there are no 
standardized standard operating procedures or regulatory test 
guidelines for the in vitro comet assay, so a diverse range of 
methods and cell test systems have been employed leading to 
variable results for both chemicals and ENMs.[112] With specific 
respect to ENM genotoxicity assessment, there are some con-
cerns regarding the interactions between ENMs and the comet 
assay. Some studies have reported the presence of ENMs in the 
“comet head” which could give rise to misleading results.[113] 
However, comparisons between the in vitro comet and micro-
nucleus assays have shown that out of a total 70 ENMs tested, 
48 (69%) were reported as positive for genotoxicity consistently 
in both assays.[113] It is important to note, just like the afore-
mentioned genotoxicity assays, that high cytotoxicity is a major 
contributor to the misleading positive rate.[112,114,115] Yet, there 
is no definitive consensus on acceptable cytotoxicity ranges for 
the in vitro comet assay specifically. The limitations with the 
in vitro comet assay have been illustrated by Elespuru et  al., 
whereby following an extensive literature review, only 55% of 
the 22 papers identified that used the in vitro comet assay to 
evaluate ENM for DNA damage induction, met the acceptability 
criteria.[112] With specific respect to more complex 3D and cocul-
ture models, it is not always possible to discriminate among 
multiple cell types using the comet assay, as all cells are lysed 
prior to analysis.  Thus, further development of the in vitro 
comet approach is required to ensure it is both nano-specific 
and can be robustly applied to the evaluation of 3D models.
Another novel method to detect genotoxicity or DNA damage 
induced by ENMs utilizes a BAC–GFP transformed HepG2 cell 
line, cultured in a 3D format.[75,90,116,117] Here, key genes in the 
P53-mediated DNA damage response signaling pathway, such 
as P53, P21, MDM2, and BTG2, are tagged with GFP using a 
BAC recombineering technique allowing the detection of the 
activation of DNA damage signaling upon exposure at single 
cell level when combined with confocal microscopy.[117,118] In 
response to double stranded breaks in the DNA induced by a 
genotoxic agent (e.g., chemicals and ENMs), the DNA damage 
response will be activated through the recruitment of ataxia tel-
angiectasia mutated and ataxia telangiectasia, and Rad3-related 
protein at the DNA damage loci. Activation of checkpoint 
kinases 1 and 2 (CHK1 and CHK2) ensues and subsequent 
post-translational modification and activation of transcription 
factor tumor protein 53 (P53) occurs. This, in turn, leads to 
activation of its downstream target genes, such as P21, MDM2, 
and BTG2, aiming for cell cycle arrest, DNA repair, or apop-
tosis.[119] Therefore, these reporter genes reflect and highlight 
the DNA damage response pathway mediated by P53 well at 
different levels within the signaling cascade. Gene activation/
deactivation is time sensitive, in that genes at the beginning of 
the pathway cascade will be activated and initiated much earlier 
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than those further downstream. Subsequently, it is important to 
consider the optimum window of opportunity for gene activity 
to be assessed, as those genes targeted can often reflect the 
exposure time required to be undertaken.
When combining these HepG2 DNA damage BAC–GFP 
reporters with live cell confocal microscopy, the activation 
dynamics of the critical DNA damage signaling genes can be 
monitored frequently over extended periods of time at single cell 
level.[90] Studies have shown that culturing these HepG2 reporter 
cells in Matrigel for 21 days resulted in the formation of stable 
spheroids with an improved hepatic phenotype. This includes 
increased albumin secretion, cytochrome P450 activity, phase II 
conjugation enzyme and transporter expression, and activation of 
hepatic differentiation transcription factors, such as HNF4alpha, 
C/EBP, and STAT1.[75,90] Furthermore, these spheroids stop 
proliferating after 7 to 14 days of culture and remain stable 
for multiple weeks allowing the testing of long-term repeated 
exposures.[75,90] By utilizing these DNA damage HepG2 GFP 
reporters in both 2D and 3D systems, Hiemstra et  al. showed 
a dose and time-dependent activation of the DNA damage 
response upon exposure to genotoxic compounds emphasizing 
its suitability to identify genotoxicants.[90,120] Furthermore, the 3D 
HepG2 reporter system showed a high resemblance to chemical-
induced stress responses seen in PHH transcriptomics. This 
DNA damage HepG2 reporter system in 3D can also be applied 
for ENM-induced genotoxicity over long-term exposure regimes. 
As demonstrated in Figure 5, this system allows for the detection 
of DNA damage following 3-day exposure to both chemicals and 
ENMs using 3D spheroid HepG2 BAC–GFP reporters. Here, 
activation of P21-GFP was seen after exposure to aflatoxin B1, 
a known liver carcinogen, as well as after repeated ZnO ENM 
exposure over 3 days. However, since these spheroids were 
formed using a scaffold, as previously reported, it is likely the 
penetration of ENMs into the spheroid, and uptake by the cells 
may be hindered due to the restricted motility of ENM to trans-
locate through the Matrigel scaffold. To validate this, intracellular 
measurements of ENM uptake within the spheroids should be 
undertaken. Alternatively, these HepG2 GFP reporters could 
be used in a scaffold-free 3D setting to overcome hindrance of 
ENM-penetration by the ECM to allow for improved uptake of 
ENMs within the spheroids.
In conclusion, there are number of suitable in vitro geno-
toxicity assays available, but they do require optimization and 
further development to facilitate their application to 3D liver 
models, in order to provide a comprehensive evaluation of the 
genotoxicity induced post-acute and long-term ENM exposure.
8. Discussion and Future Directions
It is important to consider the suitability of the 3D in vitro 
hepatic models currently available for genotoxicity evaluation, 
given that DNA damage is an important key event in hepato-
cellular carcinoma etiology. Although the four AOPs related to 
human liver cancer development that have been submitted to 
the OECD AOP-wiki are still under review, they highlight the 
following key biochemical endpoints: disruption to the hepatic 
homeostatic balance in favor of cell growth, reduced apoptotic 
activity, increased cell proliferation, hyperplasia in several liver 
cell types, and clonal expansion of preneoplastic foci cells.[35] 
Figure 5. Mapping of the DNA damage response activation by the utility of HepG2 DNA damage reporters P21 induction upon DNA damage signaling 
in HepG2 cells. In the left panel, a schematic representation of the p53-mediated DNA damage response is shown. Genes in green can be monitored by 
the usage of specific HepG2 DNA damage reporters (P53, BTG2, MDM2, and P21). In the right panel as an example, the activation of P21-GFP HepG2 
reporter upon exposure is shown. HepG2 P21-GFP spheroids grown in Matrigel were repeatedly exposed for 3 days to 5 µm aflatoxin B1 or 100 µg mL−1 
ZnO and imaged using a confocal microscope with a at 20× objective. Cells were stained with Hoechst for nuclei visualization and propidium iodide 
for viability.
Small 2021, 2006055
2006055 (15 of 19)
www.advancedsciencenews.com
© 2021 The Authors. Small published by Wiley-VCH GmbH
www.small-journal.com
These parameters represent important targets that a hepatic 3D 
model should be able to report upon in order to provide a reli-
able prediction of carcinogenicity. When selecting key events 
to target, consideration should be given to the natural timeline 
of liver adverse outcomes. For example, liver cirrhosis arises 
as a result of prolonged exposure to hepatotoxicants causing 
repeated scarring of the hepatic tissue, known as liver fibrosis. 
Consequently, in order to supersede in vivo toxicity testing, 3D 
in vitro liver models must remain viable, while maintaining 
phenotypic functionality and stable biotransformation com-
petence over an extended period of time. This principle has 
received a lot of attention in the recent scientific literature, with 
a number of 3D models adapted to support prolonged culture 
over 14 days and up to a month in some cases.[74,83,120] Not only 
does this development allow for more environmentally relevant 
long-term, repeated ENM exposures to be assessed, it also pro-
vides potential for the evolution of hepatic AOPs to be studied 
in a more comprehensive manner.
It is necessary to acknowledge that liver cancer progres-
sion usually evolves from DNA damage in conjunction with 
the loss of effective DNA damage repair mechanisms, coupled 
to induction of oncogenes or loss of tumor suppressor genes, 
such as P53.[62] A number of studies using 3D liver models 
have found that exposure to ENMs can induce genotoxicity 
in the form of DNA strand breaks and gross chromosomal 
damage,[74,80,98] but the majority of these studies do not take 
into account DNA repair capabilities or the high regeneration 
capacity of hepatocytes. As a result, regulatory-approved geno-
toxicity assays, like the CBMN assay or mutation-based assays 
that accommodate for DNA repair, should be the primary 
focus when adapting existing 3D liver models to support these 
endpoints. One major limitation of current 3D models, is the 
inability to support assays that typically detect point mutations 
(i.e., the mouse lymphoma assay [OECD 490] and the HPRT 
assay [OECD 476]). As DNA damage can be induced in mul-
tiple forms and no single assay can detect all forms of damage 
simultaneously, it is important to consider 3D models that are 
able to support an array of genotoxicity endpoints spanning 
point mutations, clastogenicity and aneugenicity, or other key 
events (e.g., cell proliferation, oxidative stress, apoptosis, and 
inflammation) identified in the AOP frameworks. While several 
of the key events have been identified to date, the molecular ini-
tiating events, particularly associated with ENM exposure, are 
less understood.[121] Thus, future studies should aim to identify 
nano-specific molecular initiating events that should form pri-
mary targets for development of novel in vitro testing strate-
gies for hepatic disease etiology. In this manner, AOP networks 
could form part of a decision tree and be utilized as a founda-
tion for establishing the most suitable in vitro test systems and 
biochemical assay endpoints for ENM hazard assessment.[122]
Another vital aspect of nano(geno)toxicology and the prin-
ciple mechanism for genotoxicity in vivo is secondary genotox-
icity, yet it remains largely overlooked within current 3D in vitro 
liver models.[27–29] To fully emulate the mechanisms underlying 
ENM associated genotoxicity, further advancement to the cur-
rent 3D hepatic models needs to incorporate additional immune 
cell lines (e.g., macrophages and neutrophils). For example, 
human hepatocyte and Kupffer cell coculture models are well 
established in a 2D format, but immune cells are not often 
incorporated within a 3D approach, especially models with the 
capability to support genotoxicity assays. Although PHH cocul-
ture models are available to provide a more physiologically rel-
evant alternative to in vivo toxicology models, consisting not 
only of human Kupffer cell macrophages but the entire non-
parenchymal fraction including LSECs and stellate cells, these 
models are expensive and exhibit donor–donor variability in 
comparison to more rudimentary coculture models.[123] Further-
more, having the addition of multiple cells types means that 
each cell would have to be individually identified and scored 
independently for genotoxic events. This process could make 
an already labor-intensive task even more time-consuming. 
Based on this, future work should be focused toward devel-
oping stable, proliferative 3D coculture liver models. Resident 
liver macrophages have pre-eminent importance as they play 
a major role in the mediation of secondary genotoxicity due 
to their ability to phagocytose ENM and subsequently induce 
a sustained inflammatory response and oxidative stress.[27,106] 
Therefore, models which include multiple cell types, specifi-
cally Kupffer cells, in a 3D environment would be beneficial to 
characterize the hazards and adverse outcomes associated with 
ENM exposure in a more comprehensive manner.
In conclusion, adverse outcome pathways provide a useful 
tool for predicting specific mechanisms behind hepatotoxicity 
and should be taken into consideration throughout the devel-
opment and refinement of in vitro test systems and relevant 
bioassays. This is necessary to maintain their physiological rel-
evance and support these key events as more data are released. 
A major challenge has been the development of complex in 
vitro liver models which combine tissue-like functionality, 
xenobiotic metabolism competency, and retention of hepatic 
phenotypic characteristics over prolonged culture periods, 
whilst being compatible with multiparametric hazard endpoint 
analysis. Consequently, it may be beneficial to coalesce advanta-
geous aspects of the existing 3D in vitro model technologies. 
For example, select the most phenotypically functional hepatic 
cell line and adapt the current culture system to mimic the 
setup of another model that has proven to enhance the physi-
ological relevance, longevity, and compatibility for genotoxicity 
assessment. Conversely, individual models could be developed 
independently to address particular target endpoints, that is, 
PHH models for metabolism-based assessments and toxicity 
screening, whilst HepG2 spheroid models would be utilized 
for genotoxicity endpoints. Whilst multiple models are likely 
to be necessary to ensure predictive in vitro test systems, it is 
important to minimize the number of models required to sup-
port all relevant hazard characterization endpoints as in vitro 
approaches need to remain cost-effective and easy to implement 
in an industrial safety assessment setting. Although substantial 
advancements have been made, a need for high-throughput, 
robust, and physiologically relevant hepatic models capable of 
supporting comprehensive genotoxicity assessment following 
ENM exposure remains to be fully established.
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